Immuron Limited
Immuron Limited
Your view on IMC.AX
Overview
What the company does, where it operates, and who runs it.
About Immuron Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Steven George Lydeamore
- Headquarters
- 62 Lygon Street, Carlton, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Steven George Lydeamore
- Headquarters
- 62 Lygon Street, Carlton, VIC, AU
Immuron Limited, an Australian biopharmaceutical firm founded in 1994 and headquartered in Carlton, is dedicated to the exploration, advancement, and worldwide commercialization of polyclonal antibodies.
Operating across two divisions—Research and Development, and Hyperimmune Products—the company serves markets in Australia, Israel, Canada, the United States, and other international regions.
Its current product portfolio includes Travelan, an over-the-counter remedy aimed at reducing the likelihood of travelers' diarrhea and minor gastrointestinal complaints, which also functions as a dietary supplement for digestive well-being and gut protection.
Another offering, Protectyn, is an immune supplement formulated to bolster healthy digestive function and liver support. Beyond its commercialized products, Immuron is actively progressing several pipeline candidates.
Travelan (IMM-124E) is currently undergoing a Phase III registration trial in the United States for the prevention of travelers' diarrhea, alongside a Phase II field trial for the same indication, and has demonstrated antiviral efficacy against SARS-CoV-2.
Concurrently, IMM-529 is in Phase I/IIa clinical trials, targeting patients with recurrent Clostridium difficile infections.
The company has also established key research alliances, including an agreement with the Naval Medical Research Center to develop and clinically evaluate a therapeutic agent against Campylobacter and enterotoxigenic Escherichia coli infections, and a collaborative effort with the Walter Reed Army Institute of Research to create an oral treatment for shigellosis.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Immuron Limited. Starting points for Immuron Limited: EPS -AUD 0.01, beta 0.50 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Immuron Limited. Immuron Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Immuron Limited. Trailing twelve-month EPS for Immuron Limited stands at -AUD 0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Earnings Estimate
| EPS | Current QtrJun 2018 | Next QtrDec 2024 | Current YearFY Jun 2017 | Next YearFY Jun 2018 |
|---|---|---|---|---|
| Avg. estimate | −AUD 0.13 | −AUD 0.00 | −AUD 0.16 | −AUD 0.04 |
| Low estimate | −AUD 0.13 | −AUD 0.00 | −AUD 0.16 | −AUD 0.04 |
| High estimate | −AUD 0.12 | −AUD 0.00 | −AUD 0.16 | −AUD 0.04 |
| No. of analysts | 2 | 1 | 1 | 1 |
| Year-ago EPS | — | — | — | — |
| Growth | — | — | — | — |
Revenue Estimate
| Revenue | Current QtrJun 2018 | Next QtrDec 2024 | Current YearFY Jun 2017 | Next YearFY Jun 2018 |
|---|---|---|---|---|
| Avg. estimate | AUD 2.58M | AUD 4.02M | AUD 1.82M | AUD 2.99M |
| Low estimate | AUD 2.46M | AUD 4.02M | AUD 1.82M | AUD 2.99M |
| High estimate | AUD 2.59M | AUD 4.02M | AUD 1.82M | AUD 2.99M |
| No. of analysts | 2 | 1 | 1 | 1 |
| Year-ago revenue | — | — | — | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Immuron Limited. Immuron Limited has reported as a listed company since 1999. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| AT1.AXAtomo Diagnostics Limited | Healthcare | Medical - Devices | — | ||
| AVE.AXAvecho Biotechnology Limited | Healthcare | Biotechnology | — | ||
| BTC.AXBTC Health Limited | Healthcare | Biotechnology | — | ||
| ENL.AXEnlitic, Inc. | Healthcare | Medical - Healthcare Information Services | — | ||
| NC6.AXNanollose Limited | Healthcare | Biotechnology | — | ||
| NOX.AXNoxopharm Limited | Healthcare | Biotechnology | — | ||
| NTI.AXNeurotech International Limited | Healthcare | Biotechnology | — | ||
| OSL.AXOncoSil Medical Ltd | Healthcare | Medical - Devices | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PAR.AXParadigm Biopharmaceuticals Limited | Healthcare | ASX | — | ||
| PARDPoniard Pharmaceuticals, Inc. | Healthcare | OTC | $150 | ||
| PASGPassage Bio, Inc. | Healthcare | NASDAQ | $12.9M | ||
| PBIGFParadigm Biopharmaceuticals Limited | Healthcare | OTC | $87.9M | ||
| PBLAPanbela Therapeutics, Inc. | Healthcare | OTC | $53,889 | ||
| PBLSParabilis Medicines, Inc. | Healthcare | NASDAQ | $3.5B | ||
| PBMPsyence Biomedical Ltd. | Healthcare | NASDAQ | $47,738 | ||
| PBMWWPsyence Biomedical Ltd. Warrant | Healthcare | NASDAQ | $869 | ||
| PBYIPuma Biotechnology, Inc. | Healthcare | NASDAQ | $373.3M | ||
| PCSAProcessa Pharmaceuticals, Inc. | Healthcare | NASDAQ | $4.8M | ||
| PCVXVaxcyte, Inc. | Healthcare | NASDAQ | $9.3B | ||
| PDSBPDS Biotechnology Corporation | Healthcare | NASDAQ | $43.8M | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Immuron Limited. Coverage tracks Immuron Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Immuron Limited.